Previous close | 17.82 |
Open | 17.75 |
Bid | 17.80 x 500 |
Ask | 17.91 x 100 |
Day's range | 17.71 - 18.22 |
52-week range | 9.50 - 18.85 |
Volume | |
Avg. volume | 1,216,482 |
Market cap | 1.613B |
Beta (5Y monthly) | 1.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
DUBLIN, Ireland, April 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference on Monday, April 8 at 10:15 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90
DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Leerink Global Biopharma Conference: Fireside chat on Monday, March 11 at 3:20 p.m. ET.UBS Virtual CNS Day: Fireside chat on Monday, March 18 at 12:30 p.m. ET. A live webcast of these events, as well as an archived
DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™. Avadel is pleased with the jury’s decision ruling in favor of Avadel with respect to one of the contested patents. As it relates to the jury’s decision against Avadel regarding the additional contested